1. Home
  2. HTCR vs MEIP Comparison

HTCR vs MEIP Comparison

Compare HTCR & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTCR
  • MEIP
  • Stock Information
  • Founded
  • HTCR 2009
  • MEIP 2000
  • Country
  • HTCR Japan
  • MEIP United States
  • Employees
  • HTCR N/A
  • MEIP N/A
  • Industry
  • HTCR EDP Services
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTCR Technology
  • MEIP Health Care
  • Exchange
  • HTCR Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • HTCR 12.8M
  • MEIP 13.3M
  • IPO Year
  • HTCR 2022
  • MEIP 2003
  • Fundamental
  • Price
  • HTCR $0.53
  • MEIP $2.20
  • Analyst Decision
  • HTCR
  • MEIP Hold
  • Analyst Count
  • HTCR 0
  • MEIP 1
  • Target Price
  • HTCR N/A
  • MEIP N/A
  • AVG Volume (30 Days)
  • HTCR 2.5M
  • MEIP 6.0K
  • Earning Date
  • HTCR 08-13-2025
  • MEIP 05-13-2025
  • Dividend Yield
  • HTCR 3.79%
  • MEIP N/A
  • EPS Growth
  • HTCR N/A
  • MEIP N/A
  • EPS
  • HTCR N/A
  • MEIP N/A
  • Revenue
  • HTCR $28,947,523.00
  • MEIP N/A
  • Revenue This Year
  • HTCR N/A
  • MEIP N/A
  • Revenue Next Year
  • HTCR $8.59
  • MEIP N/A
  • P/E Ratio
  • HTCR N/A
  • MEIP N/A
  • Revenue Growth
  • HTCR 59.42
  • MEIP 33.76
  • 52 Week Low
  • HTCR $0.49
  • MEIP $1.46
  • 52 Week High
  • HTCR $3.38
  • MEIP $4.10
  • Technical
  • Relative Strength Index (RSI)
  • HTCR 44.30
  • MEIP 50.33
  • Support Level
  • HTCR $0.54
  • MEIP $2.21
  • Resistance Level
  • HTCR $0.53
  • MEIP $2.40
  • Average True Range (ATR)
  • HTCR 0.04
  • MEIP 0.10
  • MACD
  • HTCR -0.00
  • MEIP -0.00
  • Stochastic Oscillator
  • HTCR 23.75
  • MEIP 33.33

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: